Latest From Medpace Inc.
Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.
IQVIA has impressed industry observers with its Q4 results, which show the potential of the freshly merged company, especially in its technology division. With biotech money and strategic outsourcing as prevalent as it has been in recent memory, could the rest of the CRO industry follow suit?
The contract services industry is reaping the rewards of a resilient biotech funding environment, re-accelerating growth in the sector.
This week's roundup includes CEO appointments by Tiziana and Ergomed and executive appointments by Crescendo Biologics, Ablynx, Alexion and Axcella. In addition to this, Oxford BioTherapeutics and Kymab have announced board appointments.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Medpace Inc.
- Senior Management
August J Troendle, MD, President & CEO
Jesse Geiger, CPA, COO, Lab Ops and CFO
- Contact Info
Phone: (513) 579-9911
5375 Medpace Way
Cincinnati, OH 45227
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.